At what renal function thresholds should metformin be held in acute kidney injury (AKI) or chronic kidney disease (CKD)?

Metformin Threshold in AKI and CKD

Stop metformin immediately when eGFR falls below 30 mL/min/1.73 m² in both chronic kidney disease and acute kidney injury. 122

Clear eGFR-Based Thresholds

The 2022 KDIGO guidelines provide an algorithmic approach to metformin management based on kidney function 1:

eGFR < 30 mL/min/1.73 m²

• STOP metformin immediately - both for existing users and do not initiate in new patients
• This applies to both CKD and AKI
• This is a hard contraindication per FDA labeling 22

eGFR 30-44 mL/min/1.73 m²

• Reduce dose by 50% if already on metformin
• Do NOT initiate metformin in new patients at this level 2
• Monitor eGFR every 3-6 months

eGFR 45-59 mL/min/1.73 m²

• Continue current dose in most patients
• Consider dose reduction in specific high-risk situations:
  • Concurrent illness causing dehydration
  • Planned contrast imaging procedures
  • Acute intercurrent illness
  • Concomitant use of drugs affecting renal function
• Monitor eGFR every 3-6 months 1

eGFR ≥ 60 mL/min/1.73 m²

• Continue full dose
• Monitor eGFR at least annually

Critical Situations Requiring Immediate Metformin Discontinuation

Beyond the eGFR < 30 threshold, hold metformin immediately in these acute scenarios regardless of baseline eGFR 2:

• Acute kidney injury of any severity - even if baseline eGFR was normal
• Iodinated contrast procedures when eGFR 30-60 mL/min/1.73 m² (hold at time of or prior to procedure; restart only after confirming stable renal function at 48 hours) 22
• Acute dehydration or volume depletion
• Sepsis or systemic infection
• Acute heart failure or cardiogenic shock
• Acute myocardial infarction
• Hypoxemia or respiratory failure
• Hepatic impairment (new or acute)
• Surgery requiring NPO status

Rationale and Evidence Quality

The eGFR < 30 threshold is based on the risk of metformin accumulation and lactic acidosis 2. While metformin-associated lactic acidosis is rare (6/100,000 patient-years), it carries high mortality when it occurs 3. The FDA labeling explicitly contraindicates metformin below eGFR 30 22, and the 2022 KDIGO guidelines (the most recent authoritative guideline) align with this threshold 1.

Important nuance: The 2025 ADA Standards of Care specify that metformin should not be started when eGFR < 45 mL/min/1.73 m², but can be continued with dose reduction down to eGFR 30 4. This creates a practical distinction between initiation and continuation thresholds.

Common Pitfalls to Avoid

1. Don't rely on serum creatinine alone - always calculate eGFR, as creatinine can be misleading in elderly, malnourished, or low muscle mass patients 5

2. Don't forget to hold metformin during acute illness - even patients with normal baseline eGFR can develop AKI with metformin accumulation during acute dehydration, infection, or other stressors 6

3. Don't restart metformin after contrast without checking renal function - wait 48 hours and confirm stable eGFR before restarting 2

4. Don't ignore the dose reduction zone (eGFR 30-44) - continuing full doses in this range increases lactic acidosis risk 1

5. Monitor more frequently when eGFR < 60 - increase from annual to every 3-6 months 1